Teva And Alvotech Add Indications For US Stelara Rival
Selarsdi Version Of Ustekinumab Approved For Crohn’s Disease And Ulcerative Colitis
Alvotech and US marketing partner Teva have celebrated a further approval for their Selarsdi ustekinumab biosimilar rival to Stelara that encompasses a new presentation as well as a label expansion to include adults with Crohn’s disease and ulcerative colitis.
